{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-129531","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2025-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.753690+00:00","generated_at":"2026-05-20T08:29:03.087612+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ORIC raises $125M; ORIC-944 Phase 1b shows 59% PSA50 response in mCRPC","bullets":["$125M private placement of 19.2M shares/pre-funded warrants at $6.50/share; led by SR One; close expected May 29, 2025.","Pro forma cash into 2H 2027 funds through first ORIC-944 Phase 3 registrational trial primary endpoint.","ORIC-944 + AR inhibitor achieved 59% PSA50 (10/17), 47% confirmed PSA50, and 24% PSA90 (4/17) in heavily pretreated mCRPC.","Safety mostly Grade 1/2 GI events (diarrhea 53%, one Grade 3); no Grade 4/5 treatment-related AEs.","Phase 1b dose optimization in 2H 2025; first global Phase 3 registrational trial expected to start in 1H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-129531","json":"https://secwatch.observer/filing/0001193125-25-129531.json","markdown":"https://secwatch.observer/filing/0001193125-25-129531.md","text":"https://secwatch.observer/filing/0001193125-25-129531.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000119312525129531/0001193125-25-129531-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000119312525129531/d911818d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T08:29:03.087612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}